Company Analysis ОЗОН Фармацевтика
1. Summary
Disadvantages
- Price (28.91 ₽) is higher than fair price (13.51 ₽)
- Dividends (0%) are below the sector average (0%).
- The stock's return over the last year (0%) is lower than the sector average (0%).
- Current debt level 27.34% has increased over 5 years from 0%.
- The company's current efficiency (ROE=27.8%) is lower than the sector average (ROE=27.8%)
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| ОЗОН Фармацевтика | Фармацевтика | Index | |
|---|---|---|---|
| 7 days | -5.2% | -3.8% | -4.6% |
| 90 days | 0% | 0% | -5% |
| 1 year | 0% | 0% | -18% |
OZPH vs Sector: ОЗОН Фармацевтика has slightly underperformed the "Фармацевтика" sector by 0% over the past year.
OZPH vs Market: ОЗОН Фармацевтика has outperformed the market by 17.99% over the past year.
Stable price: OZPH is not significantly more volatile than the rest of the market on "Московская биржа" over the last 3 months, with typical variations of +/- 5% per week.
Long period: OZPH with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (28.91 ₽) is higher than the fair price (13.51 ₽).
Price is higher than fair: The current price (28.91 ₽) is 53.3% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (6.19) is higher than that of the sector as a whole (6.19).
P/E vs Market: The company's P/E (6.19) is lower than that of the market as a whole (14.51).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.24) is higher than that of the sector as a whole (2.24).
P/BV vs Market: The company's P/BV (2.24) is lower than that of the market as a whole (10.01).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.57) is higher than that of the sector as a whole (1.57).
P/S vs Market: The company's P/S indicator (1.57) is lower than that of the market as a whole (1.89).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (4.54) is higher than that of the sector as a whole (4.54).
EV/Ebitda vs Market: The company's EV/Ebitda (4.54) is higher than that of the market as a whole (2.21).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by 0% over the last 5 years.
Accelerating profitability: The return for the last year (55.5%) exceeds the average return for 5 years (0%).
Profitability vs Sector: The return for the last year (55.5%) is lower than the return for the sector (55.5%).
5.4. ROE
ROE vs Sector: The company's ROE (27.8%) is lower than that of the sector as a whole (27.8%).
ROE vs Market: The company's ROE (27.8%) is lower than that of the market as a whole (68.09%).
5.5. ROA
ROA vs Sector: The company's ROA (16.2%) is lower than that of the sector as a whole (16.2%).
ROA vs Market: The company's ROA (16.2%) is lower than that of the market as a whole (17.84%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (16.34%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
9. Stocks forum ОЗОН Фармацевтика
9.1. Stocks forum - Latest comments
9.2. Latest Blogs
Друзья, ну что, все выжили? Да, ЦБ, конечно, решил пощекотать нам нервишки. А заодно, снова направить наш индекс #MEZ4 в сторону снижения. Что интересно, кстати, акции самой #MOEX тоже сегодня корректировались, хотя от высокой ставки она даже выигрывает 🤔 А объемы торгов у нас уже и физики могут нагонять. В общем, хэджируемся индексом и пока наблюдаем....
More
Привет 👋 Озон фармацевтика #OZPH ожидает первую прибыль от биотеха в 2027 году. Компания достигнет предела развития на рынке дженериков и начнет активно развивать биотехнологии в 2029 году....
More
⚡️ Позитив сменился навесом продавцов. К чему готовиться инвестору.
Начало торговой недели ознаменовалось достаточно резвым ростом. Многие компании драйвели рынок новостями о предстоящих дивидендах. Индекс в моменте рост на 1%, но ближе к окончанию основной части торгов, растерял половину роста....
More
All blogs ⇨
